Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.
Glatiramer acetate treatment negatively regulates type I interferon signaling.
A meta-analysis of whole genome linkage screens in multiple sclerosis.
Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
Genzyme submits applications to FDA and EMA for approval of LEMTRADA™ (alemtuzumab) for multiple sclerosis
The INCAT disability score: A critical analysis of its measurement properties.
New Tysabri data reaffirm substantial efficacy in treatment of people with MS and demonstrate stability of anti-JCV antibody status
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.
The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation.
Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study.
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Teaching NeuroImages: MRI in advanced neuromyelitis optica.
FTY720/Fingolimod, a Sphingosine Analogue, Reduces Amyloid-β Production in Neurons.
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.
Gustatory Dysfunction in Multiple Sclerosis
URMC rheumatologist presents data showing drug’s potential to ease arthritis symptoms
Roche's MabThera approved for two vasculitis indications in UK
Rituximab for refractory digital infarcts and ulcers in systemic sclerosis.
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg
Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis.
Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes.
Food and Drug Administration drug insert for Campath (alemtuzumab)

Pages